Preclinical Drug Compound Request Program
The Takeda Preclinical Drug Compound Request Program supports investigator-initiated oncology research. As part of this program, we provide investigators with certain research and marketed compounds for eligible pre-clinical studies.
How does it work?
Prospective investigators submit their contact information and detailed study proposal to the Takeda Preclinical Drug Compound Request System. Our R&D teams review each proposal, and if the study is approved, a material transfer agreement is negotiated with the investigator's institution. Typically, the review process can take four to eight weeks from the time Takeda receives a proposal.
Upon entering the Takeda Preclinical Drug Compound Request System, an investigator is asked to create a username and password.
Once in the system, the applicant follows the prompts to provide contact information, names of any collaborators and lab interests. In Step 2, the applicant enters the goals of the study, the methods and materials (e.g. cell lines, models) to be used and the investigator's CV. When the submission is complete, applicants click the "submit" button and Takeda will begin the review process.
Investigators may track the status of requests by logging back into the Takeda Preclinical Drug Compound Request System at any time. Investigators are notified of Takeda Oncology's decision by email.
If selected, the investigator will be responsible for:
- Disclosing other relevant third party affiliations (collaborators, compounds, cell lines, models)
- Submitting twice yearly data/status updates
- Informing Takeda of any study related milestones or events
- Informing Takeda if the investigator transfers to a new institution
- Delivering any draft manuscripts based on the research according to the negotiated terms of the material transfer agreement